PL3099302T3 - Formy krystaliczne 2-(tert-butyloamino)-4-((1r,3r,4r)-3-hydroksy-4-metylocykloheksyloamino) -pirymidyno-5-karboksyamidu - Google Patents

Formy krystaliczne 2-(tert-butyloamino)-4-((1r,3r,4r)-3-hydroksy-4-metylocykloheksyloamino) -pirymidyno-5-karboksyamidu

Info

Publication number
PL3099302T3
PL3099302T3 PL15743503T PL15743503T PL3099302T3 PL 3099302 T3 PL3099302 T3 PL 3099302T3 PL 15743503 T PL15743503 T PL 15743503T PL 15743503 T PL15743503 T PL 15743503T PL 3099302 T3 PL3099302 T3 PL 3099302T3
Authority
PL
Poland
Prior art keywords
methylcyclohexylamino
butylamino
carboxamide
pyrimidine
tert
Prior art date
Application number
PL15743503T
Other languages
English (en)
Polish (pl)
Inventor
Antonio Christian Ferretti
Hon-Wah Man
Jale Muslehiddinoglu
Jean Xu
Kelvin Hin-Yeong Yong
Marie Georges Beauchamps
Mohit Atul Kothare
Nanfei Zou
Nathan Andrew Boersen
Ying Li
Robert Hilgraf
Mark A. Nagy
Daozhong Zou
Lianfeng Huang
Original Assignee
Signal Pharmaceuticals, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53678405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3099302(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Signal Pharmaceuticals, Llc filed Critical Signal Pharmaceuticals, Llc
Publication of PL3099302T3 publication Critical patent/PL3099302T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL15743503T 2014-01-30 2015-01-29 Formy krystaliczne 2-(tert-butyloamino)-4-((1r,3r,4r)-3-hydroksy-4-metylocykloheksyloamino) -pirymidyno-5-karboksyamidu PL3099302T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461933636P 2014-01-30 2014-01-30
US201462025161P 2014-07-16 2014-07-16
EP15743503.3A EP3099302B1 (en) 2014-01-30 2015-01-29 Crystalline forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
PCT/US2015/013412 WO2015116755A2 (en) 2014-01-30 2015-01-29 Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use

Publications (1)

Publication Number Publication Date
PL3099302T3 true PL3099302T3 (pl) 2021-03-08

Family

ID=53678405

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15743503T PL3099302T3 (pl) 2014-01-30 2015-01-29 Formy krystaliczne 2-(tert-butyloamino)-4-((1r,3r,4r)-3-hydroksy-4-metylocykloheksyloamino) -pirymidyno-5-karboksyamidu

Country Status (32)

Country Link
US (7) US9365524B2 (enExample)
EP (2) EP3738954A1 (enExample)
JP (3) JP2017504632A (enExample)
KR (2) KR102505677B1 (enExample)
CN (3) CN106163523A (enExample)
AU (2) AU2015211036B2 (enExample)
BR (2) BR122020003206B1 (enExample)
CA (1) CA2938187C (enExample)
CL (1) CL2016001927A1 (enExample)
CR (1) CR20160346A (enExample)
CY (1) CY1123267T1 (enExample)
DK (1) DK3099302T3 (enExample)
EA (2) EA036964B1 (enExample)
ES (1) ES2811834T3 (enExample)
HR (1) HRP20201244T1 (enExample)
HU (1) HUE051266T2 (enExample)
IL (2) IL246931B (enExample)
LT (1) LT3099302T (enExample)
MX (3) MX391127B (enExample)
MY (1) MY180020A (enExample)
NZ (3) NZ715903A (enExample)
PE (1) PE20161437A1 (enExample)
PH (1) PH12016501472B1 (enExample)
PL (1) PL3099302T3 (enExample)
PT (1) PT3099302T (enExample)
RS (1) RS60715B1 (enExample)
SA (1) SA516371578B1 (enExample)
SG (1) SG11201606054SA (enExample)
SI (1) SI3099302T1 (enExample)
SM (1) SMT202000430T1 (enExample)
TW (1) TWI631108B (enExample)
WO (1) WO2015116755A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106946795B (zh) 2011-04-22 2020-06-02 西格诺药品有限公司 取代的二氨基甲酰胺和二氨基甲腈嘧啶，其组合物，和用其治疗的方法
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
WO2016100308A1 (en) * 2014-12-16 2016-06-23 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-jun n-terminal kinase in skin
BR112017012795A2 (pt) * 2014-12-16 2018-01-02 Signal Pharmaceuticals, Llc Formulações de 2-(terc-butilamino)-4-((1r,3r,4r)-3- hidroxi-4-metilciclo-hexilamino)-pirimidina-5- carboxamida
WO2016123291A1 (en) 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
WO2017019487A1 (en) 2015-07-24 2017-02-02 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
CN111934089B (zh) 2019-05-13 2021-10-26 华为技术有限公司 天线装置及移动终端
CN113698408B (zh) * 2020-05-22 2025-07-25 武汉朗来科技发展有限公司 Jnk抑制剂、其药物组合物和用途

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH549339A (de) 1971-05-12 1974-05-31 Ciba Geigy Ag Herbizides mittel.
US5852028A (en) * 1995-12-18 1998-12-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5935966A (en) * 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5811428A (en) * 1995-12-18 1998-09-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
ES2308821T3 (es) 1997-12-15 2008-12-01 Astellas Pharma Inc. Nuevos derivados de pirimidin-5-carboxamida.
JP2002523497A (ja) 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
WO2000075113A1 (en) 1999-06-09 2000-12-14 Yamanouchi Pharmaceutical Co., Ltd. Novel heterocyclic carboxamide derivatives
WO2000076980A1 (en) 1999-06-10 2000-12-21 Yamanouchi Pharmaceutical Co., Ltd. Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
US7429599B2 (en) * 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US7122544B2 (en) * 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003220968A1 (en) 2002-03-28 2003-10-13 Kyowa Hakko Kogyo Co., Ltd. Anti-inflammatory agent
MXPA04012855A (es) * 2002-06-28 2005-04-19 Yamanouchi Pharma Co Ltd Derivado de diaminopirimidincarboxiamida.
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
EP1576134B1 (en) * 2002-12-09 2013-03-06 Judith Kelleher-Andersson Method for discovering neurogenic agents
JPWO2004054617A1 (ja) 2002-12-13 2006-04-20 協和醗酵工業株式会社 中枢疾患の予防および／または治療剤
EP1590334B1 (en) 2003-01-30 2009-08-19 Boehringer Ingelheim Pharmaceuticals Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
EP2287156B1 (en) 2003-08-15 2013-05-29 Novartis AG 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
BRPI0414736A (pt) 2003-09-24 2006-11-21 Wyeth Corp 5-aril-pirimidinas como agentes anticáncer
US7956060B2 (en) 2004-03-30 2011-06-07 Kyowa Hakko Kirin Co., Ltd. Pyrimidine derivative compound
CA2571937A1 (en) 2004-07-08 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of pkc-theta
JP2008512428A (ja) 2004-09-10 2008-04-24 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング シクレソニドとＳｙｋインヒビターとの組合せ物並びにその使用方法
EP1791538A1 (en) 2004-09-10 2007-06-06 Altana Pharma AG Roflumilast and syk inhibitor combination and methods of use thereof
JP2006124387A (ja) 2004-09-30 2006-05-18 Taisho Pharmaceut Co Ltd 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法
CN101027288B (zh) 2004-09-30 2013-04-17 泰博特克药品有限公司 抑制hiv的5-取代嘧啶
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
TW200724537A (en) 2005-03-10 2007-07-01 Bayer Pharmaceuticals Corp Pyrimidine derivatives for treatment of hyperproliferative disorders
DE102005062742A1 (de) * 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
MX2009000769A (es) 2006-07-21 2009-01-28 Novartis Ag Compuestos de 2,4-di(arilaminio)-pirimidin-5-carboxamida como inhibidores de cinasas jak.
US20080139531A1 (en) 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
DK2146779T3 (en) 2007-04-18 2016-11-28 Pfizer Prod Inc Sulfonylamid derivatives to treat abnormal cell growth.
JP2010525047A (ja) 2007-04-27 2010-07-22 アストラゼネカ アクチボラグ 増殖状態の処置のためのＥｐｈＢ４キナーゼ阻害剤としてのＮ’−（フェニル）−Ｎ−（モルホリン−４−イル−ピリジン−２−イル）−ピリミジン−２，４−ジアミン誘導体
BRPI0814821A2 (pt) 2007-07-16 2015-02-03 Astrazeneca Ab Composto, composição farmacêutica, e, processo para preparar um composto
US8993585B2 (en) 2007-07-17 2015-03-31 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as PKC inhibitors
SG165655A1 (en) 2008-04-16 2010-11-29 Portola Pharm Inc 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
KR101623997B1 (ko) * 2008-04-16 2016-05-24 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노－피리미딘－５－일－카르복스아미드
AU2009238590A1 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
DK2300013T4 (da) 2008-05-21 2025-02-03 Takeda Pharmaceuticals Co Phosphorderivater som kinasehæmmere
UY31929A (es) 2008-06-25 2010-01-05 Irm Llc Compuestos y composiciones como inhibidores de cinasa
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP3549934A1 (en) 2008-06-27 2019-10-09 Celgene CAR LLC Heteroaryl compounds and uses thereof
KR20110049902A (ko) 2008-09-01 2011-05-12 아스텔라스세이야쿠 가부시키가이샤 2,4-디아미노피리미딘 화합물
CN102159547A (zh) 2008-09-18 2011-08-17 安斯泰来制药株式会社 杂环甲酰胺化合物
WO2010038081A2 (en) 2008-10-03 2010-04-08 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
US9234178B2 (en) 2008-10-31 2016-01-12 Janssen Biotech, Inc. Differentiation of human pluripotent stem cells
WO2010080864A1 (en) 2009-01-12 2010-07-15 Array Biopharma Inc. Piperidine-containing compounds and use thereof
US8470835B2 (en) * 2009-01-13 2013-06-25 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of Syk kinase
EP2389373B1 (en) 2009-01-21 2017-05-17 Rigel Pharmaceuticals, Inc. Derivatives of n2-(3-pyridyl or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases
US8367689B2 (en) * 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
PT2428508E (pt) * 2009-05-08 2016-02-29 Kotobuki Pharmaceutical Co Ltd Composto diamino-carboxamida heterocíclico
WO2010144468A1 (en) 2009-06-10 2010-12-16 Abbott Laboratories 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
JP2012197231A (ja) 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
WO2011065800A2 (ko) 2009-11-30 2011-06-03 주식회사 오스코텍 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
US20110130415A1 (en) * 2009-12-01 2011-06-02 Rajinder Singh Protein kinase c inhibitors and uses thereof
CA2801781C (en) 2010-07-21 2018-02-27 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
US8580805B2 (en) * 2010-08-31 2013-11-12 Hubert Maehr Pyrimidine carboxamide derivatives
US20130252917A1 (en) 2010-09-30 2013-09-26 Portola Pharmaceuticals, Inc. Combination therapy of 4-(3-(2h-1,2,3-triazo-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide and fludarabine
US20130244963A1 (en) 2010-09-30 2013-09-19 Portola Pharmaceuticals, Inc. Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
CN106946795B (zh) 2011-04-22 2020-06-02 西格诺药品有限公司 取代的二氨基甲酰胺和二氨基甲腈嘧啶，其组合物，和用其治疗的方法
EP2833889B1 (en) * 2012-04-04 2017-11-01 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
US9062068B2 (en) * 2012-12-04 2015-06-23 Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof
EP2970275B1 (en) * 2013-03-14 2018-05-09 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
WO2015039613A1 (zh) * 2013-09-18 2015-03-26 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
US9556126B2 (en) * 2013-12-20 2017-01-31 Signal Pharmaceuticals, Llc Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
NZ715903A (en) * 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
BR112017012795A2 (pt) * 2014-12-16 2018-01-02 Signal Pharmaceuticals, Llc Formulações de 2-(terc-butilamino)-4-((1r,3r,4r)-3- hidroxi-4-metilciclo-hexilamino)-pirimidina-5- carboxamida
WO2016123291A1 (en) * 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide

Also Published As

Publication number Publication date
HUE051266T2 (hu) 2021-03-01
CL2016001927A1 (es) 2017-02-24
US20200078359A1 (en) 2020-03-12
CA2938187A1 (en) 2015-08-06
PH12016501472A1 (en) 2016-08-22
AU2020202146A1 (en) 2020-04-16
SG11201606054SA (en) 2016-08-30
IL246931B (en) 2020-06-30
RS60715B1 (sr) 2020-09-30
MX373804B (es) 2020-03-24
TWI631108B (zh) 2018-08-01
US9814713B2 (en) 2017-11-14
CN113717109A (zh) 2021-11-30
MY180020A (en) 2020-11-19
CA2938187C (en) 2022-08-09
PE20161437A1 (es) 2017-01-07
EA201691544A1 (ru) 2017-01-30
EA031671B1 (ru) 2019-02-28
NZ715903A (en) 2017-06-30
WO2015116755A3 (en) 2015-11-12
EA036964B1 (ru) 2021-01-20
AU2015211036A1 (en) 2016-08-11
JP2017504632A (ja) 2017-02-09
EP3738954A1 (en) 2020-11-18
US20220378785A1 (en) 2022-12-01
CY1123267T1 (el) 2021-12-31
KR20160113269A (ko) 2016-09-28
BR112016017776A2 (pt) 2017-08-08
PT3099302T (pt) 2020-08-27
WO2015116755A8 (en) 2016-09-22
BR122020003206B1 (pt) 2023-02-07
US20180028534A1 (en) 2018-02-01
PH12016501472B1 (en) 2019-05-31
SI3099302T1 (sl) 2020-10-30
BR112016017776A8 (pt) 2020-06-30
US11241430B2 (en) 2022-02-08
EA201792281A1 (ru) 2018-03-30
IL246931A0 (en) 2016-09-29
EP3099302B1 (en) 2020-06-17
EP3099302A2 (en) 2016-12-07
KR102505677B1 (ko) 2023-03-03
AU2020202146B2 (en) 2021-11-18
WO2015116755A2 (en) 2015-08-06
HRP20201244T1 (hr) 2020-11-13
IL275305B (en) 2021-12-01
US20160256459A1 (en) 2016-09-08
DK3099302T3 (da) 2020-08-24
SA516371578B1 (ar) 2019-09-01
MX2019005715A (es) 2019-08-12
JP7317768B2 (ja) 2023-07-31
TW201615627A (zh) 2016-05-01
US10517873B2 (en) 2019-12-31
NZ629885A (en) 2016-04-29
SMT202000430T1 (it) 2020-09-10
MX391127B (es) 2025-03-21
US20190167678A1 (en) 2019-06-06
AU2015211036B2 (en) 2020-05-21
CN113717110A (zh) 2021-11-30
JP2019142893A (ja) 2019-08-29
LT3099302T (lt) 2020-09-10
NZ761068A (en) 2023-02-24
KR20220051440A (ko) 2022-04-26
JP6742466B2 (ja) 2020-08-19
US9365524B2 (en) 2016-06-14
ES2811834T3 (es) 2021-03-15
US20150210650A1 (en) 2015-07-30
EP3099302A4 (en) 2017-10-04
NZ722412A (en) 2022-10-28
MX2016009989A (es) 2017-02-20
JP2020183437A (ja) 2020-11-12
MX2020003173A (es) 2022-03-30
CR20160346A (es) 2016-11-23
KR102760889B1 (ko) 2025-02-03
CN106163523A (zh) 2016-11-23
US10226461B2 (en) 2019-03-12
US20250000860A1 (en) 2025-01-02
IL275305A (en) 2020-07-30

Similar Documents

Publication Publication Date Title
IL252900A0 (en) Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
IL257442A (en) Process for preparing parp inhibitor, crystalline forms and their uses
EP3136857A4 (en) Crystalline form of baricitinib
SMT202000430T1 (it) Forme cristalline di 2-(terz-butilammino)-4-((1r,3r,4r)-3-idrossi-4-metilcilcloesilammino)-pirimidin-5-carbossammide
EP3250557A4 (en) Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
SI3380554T2 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
PT3113773T (pt) Formas cristalinas do grapiprant
SG10202101979TA (en) Crystalline forms of c21h22ci2n4o2
PL3529236T3 (pl) Krystaliczne formy erawacykliny
PL3110249T3 (pl) Sposób wytwarzania mikrokapsułek biobójczych
IL253479A0 (en) Crystalline forms of efinconazole
AU358832S (en) Ear tie for correction of prominent ear deformity
IL248918A0 (en) Crystal structure of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile
PT3395819T (pt) Forma cristalina de derivado de aminopirano substituído
EP3212611A4 (en) Crystal forms of verapamil hydrochloride
GB201518589D0 (en) Crystalline form of tetraacetylethylenediamine
HK40101405A (zh) C21H22Cl2N4O2的晶型
ZA201704927B (en) Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide,compositions thereof and methods of their use
GB201402377D0 (en) Stable polymorph form B of tapentadol hydrochloride